Target stacking up on protein supplements while capitalizing on weight loss drug trend
The Impact of GLP-1 Medications on Consumer Behavior and Business Strategies
The increasing popularity of GLP-1 weight loss medications like Ozempic, Wegovy, Zepbound, and Mounjaro is not only changing how Americans eat and shop but also influencing major corporations’ business approaches.
Target’s chief merchandising officer, Lisa Roath, highlighted the significant impact of these drugs on consumer behavior. Target is adapting to emerging trends to enhance its product offerings and stay competitive in the market.
One noticeable trend is the shift towards higher-protein and higher-fiber food items driven by GLP-1 medications. Target is expanding its range of protein products and supplements to meet the growing demand among consumers using these drugs.
Additionally, as consumers focus on weight management and adopt more active lifestyles, Target is observing increased interest in apparel and home-fitness categories. The company plans to expand its offerings in these areas to cater to changing consumer preferences.
The rise of GLP-1 medications, initially developed for diabetes patients, has led to a surge in the weight loss medication market. Morgan Stanley projects significant growth in this market, with an estimated $150 billion value by 2035.
Target is not the only company adapting to this trend. Nestlé Health Science and Conagra Brands are also tailoring their products to meet the nutritional needs of consumers using GLP-1 medications. Nestlé offers personalized care and tailored products, while Conagra labels items as “GLP-1 friendly” to help consumers make informed choices.
Overall, the impact of GLP-1 medications on consumer behavior and business strategies is profound, leading to a shift towards healthier food options, increased interest in fitness-related products, and a growing market for weight loss medications.
